close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

6.735 +0.015 (+0.22%)
Streaming Delayed Price Updated: 1:36 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PT 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 8/30
Via Investor Brand Network
News headline image
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Departure of Board Member
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate at the Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
Conference call scheduled for 8:00 a.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
News headline image
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
Additional non-dilutive capital extends runway to support the launch of XPHOZAH® (tenapanor) and continued commercial investment into IBSRELA® (tenapanor) in the U.S. 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Tenapanor for Hyperphosphatemia Approved in Japan
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
Conference call scheduled for 8:00 a.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today